Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging

MOUNTAIN VIEW, Calif., Feb. 19 /PRNewswire/ -- Based on its recent analysis of the medical imaging market, Frost & Sullivan presents Naviscan, Inc. with the 2009 North American Frost & Sullivan Award for Emerging Technology of the Year. The Award recognizes the company's impressive progress in developing to market a next-generation, breast-specific PET scanner and adjunct biopsy guidance system that is set to redefine the standard of care for breast cancer patients.

Naviscan distinguished itself in 2008 as the only company to commercially offer a Positron Emission Mammography (PEM) imaging scanner as well as an adjunct PEM-guided biopsy accessory. As the market and technology leader in molecular breast imaging (MBI), the company's promising technology continues to garner the attention of some of the nation's leading women's imaging facilities, including Manhattan Diagnostic Radiology, a practice that was recently recognized as a Breast Imaging Center of Excellence by the American College of Radiology.

"MBI has rapidly created a sizeable niche market for itself as a proven adjunct technology to traditional, full-field digital mammography (FFDM)," says Frost & Sullivan Industry Analyst Travis Chong. "To capitalize on the upward trend of an aging female population with dense breast tissue and other high-risk factors, a growing number of women's imaging centers are turning to MBI, in particular PEM, in recognition of the modality's added clinical value and favorable Medicare/Medicaid and private payor reimbursement."

source; PR Newswire